Seroatlas · Human Serome Atlas

GLA

Alpha-galactosidase A

Also known as: AGAL_HUMAN, GALA

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P06280
Gene
GLA
Ensembl
ENSG00000102393
Chromosome
X
Canonical length
429 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
Secretome location
Intracellular and membrane
Quaternary structure
Homodimer

OverviewNCBI Gene

This gene encodes a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. This enzyme predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose. A variety of mutations in this gene affect the synthesis, processing, and stability of this enzyme, which causes Fabry disease, a rare lysosomal storage disorder that results from a failure to catabolize alpha-D-galactosyl glycolipid moieties. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

429 residues, UniProt reviewed canonical sequence.

>P06280|GLA
     1  MQLRNPELHL GCALALRFLA LVSWDIPGAR ALDNGLARTP TMGWLHWERF MCNLDCQEEP
    61  DSCISEKLFM EMAELMVSEG WKDAGYEYLC IDDCWMAPQR DSEGRLQADP QRFPHGIRQL
   121  ANYVHSKGLK LGIYADVGNK TCAGFPGSFG YYDIDAQTFA DWGVDLLKFD GCYCDSLENL
   181  ADGYKHMSLA LNRTGRSIVY SCEWPLYMWP FQKPNYTEIR QYCNHWRNFA DIDDSWKSIK
   241  SILDWTSFNQ ERIVDVAGPG GWNDPDMLVI GNFGLSWNQQ VTQMALWAIM AAPLFMSNDL
   301  RHISPQAKAL LQDKDVIAIN QDPLGKQGYQ LRQGDNFEVW ERPLSGLAWA VAMINRQEIG
   361  GPRSYTIAVA SLGKGVACNP ACFITQLLPV KRKLGFYEWT SRLRSHINPT GTVLLQLENT
   421  MQMSLKDLL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GLA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.24
Highest tissue expression
37 nTPM

Expression across tissuesHPA

Tissue

  • seminal vesicle: 37 nTPM
  • parathyroid gland: 30 nTPM
  • breast: 25 nTPM
  • bone marrow: 24 nTPM
  • duodenum: 21 nTPM
  • placenta: 21 nTPM

Single-cell type

  • platelets: 427 nCPM
  • cdc: 332 nCPM
  • plasma cells: 265 nCPM
  • syncytiotrophoblasts: 210 nCPM
  • neutrophils: 207 nCPM
  • macrophages: 179 nCPM

Immune cell

  • non-classical monocyte: 41 nTPM
  • intermediate monocyte: 39 nTPM
  • classical monocyte: 37 nTPM
  • myeloid DC: 30 nTPM
  • basophil: 23 nTPM
  • neutrophil: 22 nTPM

Brain region

  • white matter: 9 nTPM
  • pons: 6.8 nTPM
  • midbrain: 6.7 nTPM
  • medulla oblongata: 6 nTPM
  • thalamus: 6 nTPM
  • cerebellum: 5.3 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about GLA.

Disease | AllUniProt

Conditions GLA is implicated in, by any mechanism.

Disease | GeneticClinVar

1,124 pathogenic / likely-pathogenic of 2,028 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | ImmuneIEDB

Conditions an epitope on GLA was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.18
gnomAD pLI
1
gnomAD missense Z
1.88
DepMap mean gene effect
-0.05
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of GLA in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GLA as an antibody target. Whether an autoantibody or antibody against GLA could matter depends on whether native GLA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GLA is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label GLA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/GLA. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...